Medication-assisted treatment is one of the most effective approaches for opioid use disorder. New York has a wide network of licensed programs offering buprenorphine, methadone, and naltrexone alongside counseling.
Opioid use disorder responds well to a combination of medication and behavioral therapy. This approach, called medication-assisted treatment (MAT), uses FDA-approved medications to reduce cravings, prevent withdrawal, and lower the risk of overdose, while counseling addresses the behavioral and emotional dimensions of recovery.
In New York, MAT is available through two main types of programs. Opioid Treatment Programs (OTPs), sometimes called methadone clinics, are licensed to dispense methadone on a daily basis and also offer buprenorphine. Office-based opioid treatment (OBOT) programs allow licensed providers to prescribe buprenorphine in clinic or telehealth settings, making MAT accessible in areas without a nearby OTP.
Medication is not a replacement for counseling or recovery support. It is a medical tool that levels the playing field by reducing the physical grip of dependence, giving the behavioral work a better chance to take hold. Most programs in New York integrate both components and many also offer peer support services.
Buprenorphine (often prescribed as Suboxone, which combines buprenorphine with naloxone) is a partial opioid agonist that reduces cravings and withdrawal without producing the same high as full opioids. It can be prescribed by certified physicians, nurse practitioners, and physician assistants in office-based or telehealth settings throughout New York.
Methadone is a full opioid agonist dispensed daily (at least initially) through federally licensed OTPs. It is highly effective for people with severe opioid dependence or those who have not responded to buprenorphine. Naltrexone (brand name Vivitrol as a monthly injection) blocks the effects of opioids entirely and is a strong option for people who have already completed detox and are fully through withdrawal.
MAT is appropriate for anyone diagnosed with opioid use disorder, regardless of how long they have been using or what type of opioid is involved. It is as applicable to people dependent on prescription painkillers as to those using heroin or fentanyl.
People who have relapsed after attempting abstinence-only approaches often find that adding medication significantly changes their ability to stay in recovery. MAT is also strongly recommended for people at high risk of overdose, particularly given the potency of fentanyl now present in the illicit drug supply.
At intake, a physician or nurse practitioner evaluates your opioid use history, physical health, and withdrawal status to determine which medication and starting dose makes sense. Buprenorphine induction can often begin within hours of your last opioid use once you are in mild-to-moderate withdrawal.
Most programs require regular check-ins and counseling sessions during the early weeks of treatment. As you stabilize, visit frequency typically decreases. For methadone patients, take-home doses become available based on program policies and your progress. Counseling and peer support remain part of ongoing care throughout.
New York Medicaid covers all three MAT medications as well as the counseling services provided in OTPs and office-based programs. Commercial insurance is also required to cover MAT under federal parity rules, though prior authorization is sometimes required.
Telehealth prescribing of buprenorphine has expanded access substantially, particularly in rural and upstate areas of New York where OTPs may be far away. Many providers can conduct an initial evaluation and write a buprenorphine prescription via a video visit.
Showing 48 of 419 programs. Browse by location below or call for the full list.